Dystonia in Children and Adolescents: A Systematic Review and a New Diagnostic Algorithm
JNNP 86:774-781, Van Egmond, M.E.,et al, 2015
Dystonia
NEJM 355:818-829, Tarsy,D. &Simon,D.K., 2006
Withdrawing Amantadine in Dyskinetic Patients with Parkinson Disease
Neurol 82:300-307, Ory-Magne, F.,et al, 2014
Dystonia-Parkinson Syndrome:Differential Effects of Levodopa and Dopamine Agonists
Clin Neuropharmacol 9:298-302, Klawans,H.L.&Paleologos,N., 1986
Clinical and Radiologic Features of Pedicatric Opioid Use-Associated Neurotoxicity with Cerebellar Edema (POUNCE) Syndrome
Neurol 94:710-712, Kim, D.D. & Prasad, A.N., 2020
Involuntary Groaning Induced by Levodopa Therapy in a Patient With Progressive Supranuclear Palsy
JAMA Neurol 77:1569, Park, J.E., 2020
Lithium-Induced Reversible Pisa Syndrome
Neurol 88:e184, Kumar, N.,et al, 2017
Disorders of the Nervous System Caused by Drugs, Toxins, and Chemical Agents, Antipsychosis Drugs
Adams & Victors Principles of Neurology Chp 43, pg 1208, Ropper, A.H.,et al, 2014
Neurostimulation for Parkinsons Disease with Early Motor Complications
NEJM 368:610-622, Rau, W.,et al, 2013
The Spectrum of Statin Myopathy
Curr Opin Rheumatol 25:747-752, Mohassel, P. & Mammen, A.L., 2013
Neuro-Sweets Disease
Pract Neurol 12:126-130, Maxwel,G.,et al, 2012
High Doses of Deferiprone May Be Associated with Cerebellar Syndrome
BMJ 338:653, Beau-Salinas,F.,et al, 2009
Long-Term Effect of Initiating Pramipexole vs Levodopa in Early Parkinson Disease
Arch Neurol 66:563-570, Parkinson Sutdy Group CALM Cohort Investigators, 2009
Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009
Fourteen-Year Final Report of the Randomized PDRG-UK Trial Comparing Three Treatments in PD
Neurol 71:474-480.470, Katzenschlager,R.,et al., 2008
Functional Abnormalities Underlying Pathological Gambling in Parkinson Disease
Arch Neurol 65:1604-1611, Cilia,R.,et al, 2008
Treatment Options in the Modern Management of Parkinson Disease
Arch Neurol 64:1083-1088, Schapira,A.H.V., 2007
Compulsive Singing: Another Aspect of Punding in Parkinsons Disease
Ann Neurol 62:525-528, Bonvin,C.,et al, 2007
Cetirizine-Induced Dystonic Movements
Neurol 66:143-144, Rajput,A. &Baerg,K., 2006
Levodopa and the Progression of Parkinson's Disease
NEJM 351:2498-2508, The Parkinson Study Group, 2004
Levodopa Addiction in Non-Parkinsonian Patients
Neurol 61:1451, Steiner,I. &Wirguin,I., 2003
Dopamine Transporter Brain Imaging to Assess the Effects of Pramipexole vs Levodopa on Parkinson Disease Progression
JAMA 287:1653-1661, Parkinson Study Group, 2002
Ptosis as a Remote Effect of Therapeutic Botulinum Toxin B Injection
Neurol 59:1445-1447, Racette,B.A.,et al, 2002
Drug-Induced Pisa Syndrome (Pleurothotomus)
CNS Drugs 10:166-174, Suzuki, T. & Matsuzaka, H., 2002
Quetiapine for L-Dopa-Induced Psychosis in PD
Neurol 54:1538, Weiner,W.J.,et al, 2000
A Five-Year Study of the Incidence of Dyskinesia in Patients With Early Parkinson's Disease who were Treated with Ropinirole or Levodopa
NEJM 342:1484-1491, Rascol,O.,et al, 2000
Relation Between Cholinesterase Inhibitor and Pisa Syndrome
Lancet 355:2222, Kwak,Y.T. et al, 2000
Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease
JAMA 284:1931-1938,1971, Parkinson Study Group, 2000
Low-Dose Clozapine for the Treatment of Drug-Induced Psychosis in Parkinson's Disease
NEJM 340:757-763,801, The Parkinson Study Group, 1999
Acute Dystonia Induced by Drug Treatment
BMJ 319:623-626, vanHarten,P.N.,et al, 1999
An Algorithm (Decision Tree) for the Management of Parkinson's Disease:Trtm Guidelines
Neurol 50:S1-S57, Olanow,C.W.&Koller,W.C., 1998
Tardive Dyskinesia:Diagnosis, Pathogenesis, and Management
The Neurologist 4:180-187, Trugman,J.M., 1998
Managing the Neuropsychiatric Symptoms of Parkinson's Disease
Neurol 50:S33-S38, Lieberman,A., 1998
Investig of PDRG of UK into Excess Mortality Seen/Comb Levodopa & Selegiline Trmt in Pts with Early, Mild Parkinson's Dis
BMJ 316:1191-1196, Ben-Shlomo,Y.,et al, 1998
Tolcapone for Parkinson's Disease
The Medical Letter 40:60-61, , 1998
Catechol-O-Methyltransferase Inhibitors for Treatment of Parkinson's Disease
Lancet 351:1221-1222, Nutt,J.G., 1998
Dystonia and Chorea in Acquired Systemic Disorders
JNNP 65:436-445, Janavs,J.L.&Aminoff,M.J., 1998
Parkinson's Disease
NEJM 339:1044-1053,1130-1143, Lang,A.E.&Lozano,A.M., 1998
Managing the Late Complications of Parkinson's Disease
Neurol 49:549-557, Waters,C.H., 1997
Movement Disorders Associated with the Serotonin Selective Reuptake Inhibitors
J Clin Psychiatry 57:449-454, Leo,R.J., 1996
Drug Treatment of Parkinson's Disease
BMJ 310:575-579, Quinn,N., 1995
Low-Dose Clozapine in the Treatment of Levodopa-Induced Mental Disturbances in Parkinson's Disease
Neurol 45:432-434, Rabey,J.M.,et al, 1995
Involuntary Movement Disorders Associated with Felbamate
Neurol 45:185-187, Kerrick,J.M.,et al, 1995
Neuroleptic Drug Exposure and Treatment of Parkinsonism in the Elderly:A Case-Control Study
Am J Med 99:48-54, Avorn,J.,et al, 1995
Occurrence of Different Cancers in Patients with Parkinson's Disease
BMJ 310:1500-1501, Moller,H.,et al, 1995
Pain and Remote Weakness in Limbs Injected with Botulinum Toxin A for Writer's Cramp
Lancet 346:154-156, Sheean,G.L.,et al, 1995
Increased Incidence of Levodopa Therapy Following Metoclopramide Use
JAMA 274:1780-1782, Avorn,J.,et al, 1995
Comparison of Therapeutic Effects & Mortality Data of Levodopa & Levodopa with Selegiline in Pts with Early, Mild Parkinson's
BMJ 311:1602-1607, 15831995., Lee,A.J.,et al, 1995
Parkinson's Disease
JNNP 57:672-681, Marsden,C.D., 1994